Browse by Research Project Code

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Mitchell, R. et al. (2018) Targeting BCR-ABL independent TKI resistance in chronic myeloid leukaemia by mTOR and autophagy inhibition. Journal of the National Cancer Institute, 110(5), pp. 467-478. (doi:10.1093/jnci/djx236) (PMID:29165716) (PMCID:PMC5946859)

Pellicano, F. et al. (2018) Hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 131(14), pp. 1532-1544. (doi:10.1182/blood-2017-05-783845) (PMID:29437554) (PMCID:PMC6027092)

Zhang, B. et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nature Medicine, 24, pp. 450-462. (doi:10.1038/nm.4499) (PMID:29505034)

Vezzalini, M. et al. (2017) A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 10(1), 129. (doi:10.1186/s13045-017-0494-z) (PMID:28637510) (PMCID:PMC5479035)

Tarafdar, A. et al. (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, 129(2), pp. 199-208. (doi:10.1182/blood-2016-09-742049) (PMID:27793879) (PMCID:PMC5305055)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi:10.1182/blood-2015-08-661785) (PMID:27222476) (PMCID:PMC4991087)

Vukovic, M. et al. (2016) Adult haematopoietic stem cells lacking Hif-1α self-renew normally. Blood, 127(23), pp. 2841-2846. (doi:10.1182/blood-2015-10-677138) (PMID:27060169) (PMCID:PMC4956613)

Schemionek, M. et al. (2016) MTSS1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 30(4), pp. 823-830. (doi:10.1038/leu.2015.329) (PMID:26621336)

Karvela, M. et al. (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy, 12(6), pp. 936-948. (doi:10.1080/15548627.2016.1162359) (PMID:27168493) (PMCID:PMC4922442)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L. , Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L. and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, 128(23), pp. 2671-2682. (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (PMCID:PMC5146743)

Vukovic, M. et al. (2015) Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance. Journal of Experimental Medicine, 212(13), pp. 2223-2234. (doi:10.1084/jem.20150452) (PMID:26642852)

Aspinall-O'Dea, M., Pierce, A., Pellicano, F., Williamson, A. J., Scott, M. T. , Walker, M. J., Holyoake, T. L. and Whetton, A. D. (2015) Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nature Protocols, 10(1), pp. 149-168. (doi:10.1038/nprot.2015.007) (PMID:25521791)

Holyoake, T. L. and Helgason, G. V. (2015) Do we need more drugs for chronic myeloid leukemia? Immunological Reviews, 263(1), pp. 106-123. (doi:10.1111/imr.12234) (PMID:25510274)

Davies, A. et al. (2014) Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 96(6), pp. 694-703. (doi:10.1038/clpt.2014.176) (PMID:25188725)

Chen, Y., Peng, C., Abraham, S. A., Shan, Y., Guo, Z., Desouza, N., Cheloni, G., Li, D., Holyoake, T. L. and Li, S. (2014) Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 124(9), pp. 3847-3862. (doi:10.1172/JCI66129) (PMID:25105362) (PMCID:PMC4151200)

Gallipoli, P., Cook, A., Rhodes, S. , Hopcroft, L. , Wheadon, H. , Whetton, A. D., Jorgensen, H. G., Bhatia, R. and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi:10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Herrmann, H. et al. (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood, 123(25), pp. 3951-3962. (doi:10.1182/blood-2013-10-536078) (PMID:24778155)

Pellicano, F., Mukherjee, L. and Holyoake, T. L. (2014) Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells, 32(6), pp. 1373-1379. (doi:10.1002/stem.1678) (PMID:24520002)

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M. , Jorgensen, H.G. and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi:10.1182/blood-2013-02-485607)

Bolton-Gillespie, E. et al. (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood, 121(20), pp. 4175-4183. (doi:10.1182/blood-2012-11-466938)

Schachtner, H. et al. (2013) Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 121(13), pp. 2542-2552. (doi:10.1182/blood-2012-07-443457)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Zhang, B., Li, M., McDonald, T., Holyoake, T.L., Moon, R.T., Campana, D., Shultz, L. and Bhatia, R. (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling. Blood, 121(10), pp. 1824-1838. (doi:10.1182/blood-2012-02-412890)

Zhang, B., Ho, Y. W., Huang, Q., Maeda, T., Lin, A., Lee, S.-u., Hair, A., Holyoake, T. L., Huettner, C. and Bhatia, R. (2012) Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell, 21(4), pp. 577-592. (doi:10.1016/j.ccr.2012.02.018) (PMID:22516264) (PMCID:PMC3332001)

Karvela, M., Helgason, G. V. and Holyoake, T. L. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 12(3), pp. 381-392. (doi:10.1586/ERA.12.10)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W. and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukaemia stem cells in combination with imatinib. Cancer Cell, 21(2), pp. 266-281. (doi:10.1016/j.ccr.2011.12.020)

Soliera, A.R. et al. (2012) Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia, (doi:10.1038/leu.2012.19)

This list was generated on Fri Dec 6 10:56:32 2019 GMT.